Related Experiment Video
Updated: Jul 19, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
MR in oncology drug development
1Clinical Discovery, Bristol-Myers Squibb, Princeton, NJ 08453-4000, USA. susan.galbraith@bms.com
Abstract:
This article reviews the use of MR in preclinical and clinical experiments to aid drug development. In particular it concentrates on the use of MR to study tumor microvasculature following treatment with anti-vascular agents and the use of MRS to study tumor metabolism following treatment with a variety of anti-cancer agents. The advantages and disadvantages of a variety of techniques including contrast- and noncontrast-enhanced methods are discussed and the data from clinical trials using these techniques are reviewed. Despite the consensus documents produced to date for both dynamic contrast-enhanced MRI and MRS, most of the trials reported used alternative methods, and different nomenclature for the MR parameters used. This continues to inhibit the comparison between novel therapeutics and between different trials with the same compound. Comprehensive data from multicenter trials on the reproducibility of techniques is still lacking in the literature and the implications of the available data on clinical trial design is also discussed.
Insights
Magnetic resonance (MR) imaging and spectroscopy aid drug development by studying tumor microvasculature and metabolism. Standardized methods and nomenclature are needed for comparing novel therapeutics and improving clinical trial design.
Area of Science:
- Oncology
- Medical Imaging
- Pharmacology
Background:
- Magnetic resonance (MR) techniques are crucial for preclinical and clinical drug development.
- MR aids in studying tumor microvasculature and metabolism following anti-cancer agent treatment.
Purpose of the Study:
- To review the application of MR in drug development, focusing on tumor microvasculature and metabolism.
- To discuss the advantages and disadvantages of various MR techniques and analyze clinical trial data.
Main Methods:
- Review of preclinical and clinical experimental data using MR techniques.
- Analysis of contrast-enhanced and non-contrast-enhanced MR methods.
- Examination of data from clinical trials employing MR for therapeutic assessment.
Main Results:
- Despite consensus documents, clinical trials often use non-standardized MR methods and nomenclature.
- Inconsistent methodologies hinder the comparison of novel therapeutics and clinical trial results.
- Lack of multicenter trial data on technique reproducibility is evident.
Conclusions:
- Standardization of MR techniques and nomenclature is essential for effective drug development and clinical trial interpretation.
- Further multicenter studies are needed to establish reproducibility and guide clinical trial design.
- Consistent MR application will facilitate the evaluation of anti-vascular and anti-cancer agents.
Related Concept Videos
Treatment Resistent Cancers
Clinical Trials: Overview
Preclinical Development: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drug Discovery: Overview
